Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention - sprookjes - yvandenbroek - TriplyDB

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

http://www.wikidata.org/entity/Q26827593

about

Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles Prevention of Ovarian Hyperstimulation Syndrome: A Review Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta-analysis Androstenedione response to recombinant human FSH is the most valid predictor of the number of selected follicles in polycystic ovarian syndrome: (a case-control study)A proteomic analysis identifies candidate early biomarkers to predict ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys Application of serum anti-Müllerian hormone levels in selecting patients with polycystic ovary syndrome for in vitro maturation treatment.Bilateral renal cortical necrosis in a patient undergoing in vitro fertilization.Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial.The continuum of high ovarian response: a rational approach to the management of high responder patient subgroups.Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials.The effect of HPV infection on IVF outcomes: a systematic review and meta-analysis.Clomiphene citrate and letrozole to reduce follicle-stimulating hormone consumption during ovarian stimulation: systematic review and meta-analysis.Sliding scale HCG trigger yields equivalent pregnancy outcomes and reduces ovarian hyperstimulation syndrome: Analysis of 10,427 IVF-ICSI cycles.Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome.Counting ovarian antral follicles by ultrasound: a practical guide.Assessment of ovarian reserve by antral follicle count in ovaries with endometrioma.Low-dose hCG as trigger day and 35 hr later have different ovarian hyperstimulation syndrome occurrence in females undergoing In vitro fertilization: An RCT.GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome.Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.Follicular aspiration versus coasting for ovarian hyper-stimulation syndrome prevention.Critical care in obstetrics

P2860

Q24185870-06469C1C-F7B3-4985-81AC-CB0C5D938C13 Q26828442-4861A57F-AE97-42C4-8F4E-3D2BB33AB864 Q28070299-DAF8F6FA-8CCB-480B-928A-8D012A43690F Q33667893-800F8541-C25E-4055-8291-E1668C7D9222 Q33828136-B8DA8130-F9B0-4813-8610-3EEE49D4E249 Q33883193-00C6D70D-DF0D-4058-B585-40CEF7947E9B Q37049161-D19EFBFF-166B-45A5-9F17-1E2842BE1F8F Q37135131-1A56D645-9F2D-46F6-BB23-6AEF06303A68 Q37350477-FE7DD20D-B482-4BA7-A8F5-D1EBA011F915 Q38620147-84F3815A-FE0E-403F-8612-C68A3560384A Q38636055-EDD73141-AC5B-483D-B2C1-F97A4DAE8502 Q38728257-D64C046B-53D8-4DDD-99F6-70158EE0B17D Q38753435-65472561-DD05-4FC3-BC41-C99C1199EA81 Q40228612-EB6A16A4-D563-490E-9E29-49F2CA6CDD21 Q47653390-0E2EF816-1714-4801-8F6E-F07C89CB55CA Q47871435-37220D38-69CA-4196-8EB1-BC4D8DE080DF Q48245715-2E866BEC-8B47-41C5-9567-B0F8338AF784 Q48501929-ACDF9337-93C1-4444-A696-BA8DB52E9183 Q48517321-72E256D3-E74C-41E6-8C67-5D3260101877 Q50046268-4D8650C0-7A37-470E-8EED-A80CE57D1FE0 Q51739856-B10CEA65-C372-49A3-BCB8-385EB4CA278C Q58774610-FC35FD83-E0E2-4356-A724-3F3A95065DC4

P2860

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

http://www.wikidata.org/entity/Q26827593

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

@ast

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

@en

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

@nl

type

label

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

@ast

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

@en

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

@nl

prefLabel

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

@ast

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

@en

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

@nl

P1433

Q26827593-77D15BCE-B3D1-4675-A218-8BEF49C9F3CC

P1476

Q26827593-C760CEF2-D389-4B24-A2B5-11B90B97208D

P2093

Q26827593-481DFC19-6007-4A9D-A731-B76ADC14B024

Q26827593-61A11AC6-F3B1-4059-8122-9469349A8DCA

Q26827593-A11BE483-2AF0-4D45-B38E-6143EDFC0FFF

P2860

Q26827593-02971782-D43B-4399-AA14-FD2F1CC2052A

Q26827593-04738538-2CF8-4BC3-94C0-477A17BF9F21

Q26827593-056D2394-CAF7-4928-93B7-23FF1E4312DD

Q26827593-076C6632-EA50-44B4-9564-62DF3EA6C7CA

Q26827593-097CD2DE-DEDC-49B7-BC6F-177662125A8A

Q26827593-0B5106D9-7A67-45D7-9B7E-486CB8AECAFA

Q26827593-0CAA0CAE-8D08-4470-A121-47B281B96A79

Q26827593-0D6D63E6-F270-4CBF-B035-AAEB074691F9

Q26827593-10FED01C-C72B-44EE-A928-5EDD437FB9A5

Q26827593-13A29C76-6F55-4417-A6D3-73B8E4DF8FC2

P304

Q26827593-151D79B3-B738-4273-A7A0-59F81D62612C

P31

Q26827593-EF455907-7346-4540-8A9C-E27945DC0F66

P3181

Q26827593-E6E27E45-8C0E-4D29-85D2-4705621F4317

P356

Q26827593-7903AFB7-93FF-43CD-8CDD-E590F6DA59DF

P407

Q26827593-D5D5B1BE-EC66-44A3-B159-D80325EE97E9

P433

Q26827593-BDE00BDA-C1F8-4DDF-98D8-CC67BEA55966

P478

Q26827593-C6F94E56-3760-44B5-A6F8-3A356A185365

P50

Q26827593-806F9B3D-184B-433A-A3D0-8ADCAFB3CF98

Q26827593-C1BA076B-BBFF-4178-AFF5-4FB14E0242A4

P577

Q26827593-71926F4B-F3C4-4A4E-8F3F-ED830C10C0E6

P5875

Q26827593-3C214F32-577A-408B-9716-4FFC305D4180

P698

Q26827593-79BE1BC3-E1F6-4B71-8E7D-C74C3EFF1504

P921

Q26827593-9220A705-1AAC-4CEA-B421-7DEFD59D5ED3

P3181

P356

P1433

Ultrasound in Obstetrics and Gynecology

P1476

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

@en

P2093

D M Teixeira

http://www.w3.org/2001/XMLSchema#string

R M Moroni

http://www.w3.org/2001/XMLSchema#string

V M S Leitão

http://www.w3.org/2001/XMLSchema#string

P2860

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles

Aspirin for in vitro fertilisation

Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome

Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome

Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome

Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial

Perinatal outcomes by mode of assisted conception and sub-fertility in an Australian data linkage cohort

Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis.

P304

377-393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

535000

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/UOG.14684

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

Carolina Nastri

Wellington Martins

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266679053

http://www.w3.org/2001/XMLSchema#string

P698

25302750

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology